Using Qudexy XR to prevent migraines in children aged 6 to 11

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4 clinical trial evaluates the effectiveness of Qudexy XR in preventing migraines in children aged 6 to 11 years. Participants must have a history of migraines and experience a certain number of headache days prior to screening. The study involves administering either Qudexy XR or a placebo to assess the impact on migraine frequency and severity. The trial aims to provide insights into the safety and efficacy of this treatment in a pediatric population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subject is a female or male 6 to 11 years of age, inclusive, at Visit 1 (Screening)
2. Subject weighs at least 17.0 kg and less than 50.0 kg at Visit 1 (Screening) based on 95 percentile weight for the age range.11
3. Subject has at least a 6-month history of headaches consistent with a diagnosis of migraine with or without aura (International Classification of Headache Disorders, 3rd Edition \[ICHD 3\]).
4. Subject had ≥8 self-reported headache days in the 28 days prior to Screening.
5. Subject has a PedMIDAS score \>10, indicating at least mild disruption in daily activities, and \<140, indicating extreme disability that may require more comprehensive, multi component therapy.

Exclusion Criteria:

1. Subject has continuous migraines, defined as an unrelenting headache for a 28-day period.
2. Subject is currently receiving treatment or has used Botulinum toxin (Botox®) within 3 months prior to Visit 1 (Screening).
3. Subject is currently receiving migraine prevention medication and has initiated or changed the dose within 28 days of Screening or is unwilling to avoid making a change during the duration of the study.
4. Subject has previously failed an adequate trial of topiramate (at least 3 months duration at a clinically appropriate dose) for prophylaxis of migraine headache due to lack of efficacy or AEs.
5. Subject has previously failed an adequate trial of \>3 migraine preventative medications.
6. Subject has a known history of allergic reaction to topiramate or any excipient in Qudexy XR.
7. Subject has a diagnosis or history of disease that may interfere with safety or evaluation of the study drug.
8. Subject is currently using an investigational drug or device or has used such within 30 days prior to Visit 1.
9. Subject has begun menses and any of the following:

   1. Subject has tested positive for pregnancy; OR
   2. Subject is pregnant, planning pregnancy, or lactating; OR
   3. Subject is taking an oral hormonal contraceptive (either combined \[estrogen and progestogen containing\] or progestogen-only) and is unable or unwilling to switch to an alternative highly effective contraceptive method.

Where it's running

• Upsher-Smith Clinical Trial Site #15
  La Jolla, California, United States Recruiting
• Upsher-Smith Clinical Trial Site #14
  Tampa, Florida, United States Recruiting
• Upsher-Smith Clinical Trial Site #4
  Cincinnati, Ohio, United States Recruiting
• Upsher-Smith Clinical Trial Site #6
  Portland, Oregon, United States Recruiting
• Upsher-Smith Clinical Trials Site #7
  Springfield, Oregon, United States Recruiting
• Upsher-Smith Clinical Trial Site #9
  Huntington, West Virginia, United States Recruiting

Study contacts

• Study coordinator: PPD Laboratories
• Email: uslinfo@upsher-smith.com
• Phone: 1-877-302-2879

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HEADS Registry: Headache, Ear, Auditory, Dizziness, and Sinus</n> Registry

  This registry tests whether collecting online symptom reports from adults in the U.S. with sinus, vestibular, ear, or headache symptoms can help improve diagnosis and treatment.

  Recruiting Association of Migraine Disorders · North Kingstown, Rhode Island · NCT07754266

• MMA Embolization for Migraine: Patient-Reported Outcomes from a Single Site

  This registry tests whether adults with migraine who have or plan to have middle meningeal artery embolization notice changes in headaches and quality of life over time.

  Recruiting Cortex Neurovascular · Tacoma, Washington · NCT07652034

• Greater Occipital Nerve Block for Migraine with Medication Overuse Headache

  This study will test whether a nerve block using lidocaine and methylprednisolone can help people with migraine who overuse medications to reduce withdrawal headaches during detoxification.

  Recruiting at 2 sites Mahidol University · Bangkok, Bangkok and 2 other locations · NCT07568496

• Closing a PFO to improve glymphatic function and migraine symptoms

  This study will see if closing a patent foramen ovale (PFO) improves glymphatic system function and reduces migraine attacks in adults with PFO and migraine.

  Recruiting at 2 sites First Affiliated Hospital Xi'an Jiaotong University · Luoyang, Henan and 1 other locations · NCT07170176

• Italian Migraine Registry (I-GRAINE-NEW)

  This registry will collect past and future clinical and healthcare data from adults with episodic or chronic migraine who come to specialized headache centers in Italy to better understand how the condition evolves and is treated.

  Recruiting IRCCS San Raffaele Roma · Roma, Roma · NCT07163416

• Topical cannabidiol (Canvert-M) for migraine attacks

  This will test whether applying Canvert-M, a topical roll-on with cannabidiol and essential oils, can reduce pain during migraine attacks in adults aged 18–55.

  Recruiting Phase 4 Alasht Pharmed · Tehran · NCT07093138

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.